PH12021552422A1 - Treatment of headache using anti-cgrp antibodies - Google Patents

Treatment of headache using anti-cgrp antibodies

Info

Publication number
PH12021552422A1
PH12021552422A1 PH1/2021/552422A PH12021552422A PH12021552422A1 PH 12021552422 A1 PH12021552422 A1 PH 12021552422A1 PH 12021552422 A PH12021552422 A PH 12021552422A PH 12021552422 A1 PH12021552422 A1 PH 12021552422A1
Authority
PH
Philippines
Prior art keywords
headache
treatment
cgrp
cgrp antibodies
migraine
Prior art date
Application number
PH1/2021/552422A
Other languages
English (en)
Inventor
Roger K Cady
Joseph Hirman
Lahar Mehta
Barbara Schaeffler
Jeffrey Tl Smith
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/012781 external-priority patent/WO2020146527A1/en
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of PH12021552422A1 publication Critical patent/PH12021552422A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PH1/2021/552422A 2019-05-02 2020-02-18 Treatment of headache using anti-cgrp antibodies PH12021552422A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962842162P 2019-05-02 2019-05-02
US201962872989P 2019-07-11 2019-07-11
PCT/US2020/012781 WO2020146527A1 (en) 2019-01-08 2020-01-08 Acute treatment and rapid treatment of headache using anti-cgrp antibodies
PCT/US2020/018702 WO2020222892A1 (en) 2019-05-02 2020-02-18 Treatment of headache using anti-cgrp antibodies

Publications (1)

Publication Number Publication Date
PH12021552422A1 true PH12021552422A1 (en) 2022-07-11

Family

ID=73028680

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2021/552422A PH12021552422A1 (en) 2019-05-02 2020-02-18 Treatment of headache using anti-cgrp antibodies

Country Status (20)

Country Link
US (1) US20220251178A1 (enExample)
EP (1) EP3962522A4 (enExample)
JP (2) JP2022533030A (enExample)
KR (1) KR20220004053A (enExample)
CN (1) CN113811326A (enExample)
AU (1) AU2020267107B2 (enExample)
BR (1) BR112020027063A2 (enExample)
CA (1) CA3133571A1 (enExample)
CL (1) CL2021002866A1 (enExample)
DO (1) DOP2021000215A (enExample)
EA (1) EA202192865A1 (enExample)
GE (2) GEP20257803B (enExample)
IL (1) IL287759A (enExample)
JO (1) JOP20210247A1 (enExample)
MA (1) MA55815A (enExample)
MX (1) MX2021013426A (enExample)
PH (1) PH12021552422A1 (enExample)
SG (1) SG11202110637RA (enExample)
WO (1) WO2020222892A1 (enExample)
ZA (1) ZA202106627B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL310885A (en) * 2021-08-27 2024-04-01 H Lundbeck As Treatment of cluster headache using anti-CGRP antibodies
KR20240058082A (ko) 2021-09-15 2024-05-03 하. 룬드벡 아크티에셀스카브 항-cgrp 항체 투약 및 스크리닝 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107827982B (zh) * 2011-05-20 2021-07-06 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
PE20141787A1 (es) * 2011-05-20 2014-12-07 Alderbio Holdings Llc Composiciones anti-cgrp y uso de las mismas
AU2015230933B2 (en) * 2014-03-21 2020-08-13 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
TWI799849B (zh) * 2015-04-24 2023-04-21 美商安美基公司 治療或預防偏頭痛之方法
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
EP3448427A1 (en) * 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
CN109952314A (zh) * 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
WO2020146527A1 (en) * 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Acute treatment and rapid treatment of headache using anti-cgrp antibodies

Also Published As

Publication number Publication date
KR20220004053A (ko) 2022-01-11
MA55815A (fr) 2022-03-09
CL2021002866A1 (es) 2022-06-17
AU2020267107A1 (en) 2021-10-07
EP3962522A4 (en) 2023-07-19
BR112020027063A2 (pt) 2021-11-16
ZA202106627B (en) 2025-12-17
CA3133571A1 (en) 2020-11-05
IL287759A (en) 2022-01-01
JP2026016471A (ja) 2026-02-03
GEP20257803B (en) 2025-10-10
EA202192865A1 (ru) 2022-02-14
WO2020222892A1 (en) 2020-11-05
GEAP202515803A (en) 2025-06-10
EP3962522A1 (en) 2022-03-09
JOP20210247A1 (ar) 2023-01-30
JP2022533030A (ja) 2022-07-21
US20220251178A1 (en) 2022-08-11
CN113811326A (zh) 2021-12-17
MX2021013426A (es) 2021-12-10
SG11202110637RA (en) 2021-10-28
AU2020267107B2 (en) 2026-04-09
DOP2021000215A (es) 2021-11-21

Similar Documents

Publication Publication Date Title
MX2021004059A (es) Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas.
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
WO2020006374A3 (en) Anti-sirp-beta1 antibodies and methods of use thereof
MX2019010397A (es) Seleccion de pacientes de cefalea que responden a anticuerpos dirigidos contra el peptido relacionado con el gen de la calcitonina.
GEAP202515689A (en) Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies
ZA202202363B (en) Antibodies against ilt2 and use thereof
EP4623992A3 (en) Antibodies specifically binding to human il-1r7
PH12018502538A1 (en) Antibodies to alpha-synuclein and uses thereof
MA53765B2 (fr) Tubulysines et conjugués tubulysines-protéines
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
EA202190235A1 (ru) Антитела к cd33 и способы их применения
PH12020500205A1 (en) Anti-cd147 antibody
MX2026002776A (es) Proteinas de union al antigeno biespecificas anti-receptor de cgrp/anti-receptor pac1
PH12022551398A1 (en) Anti-mertk antibodies and methods of use thereof
EA202092593A1 (ru) Белки, связывающие каннабиноидный рецептор 1-го типа (cb1), и их применение
NZ762312A (en) Anti-pacap antibody
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
ZA202302392B (en) Antibodies against ilt2 and use thereof
ZA202106627B (en) Treatment of headache using anti-cgrp antibodies
MX2022002235A (es) Combinacion de urolitina con el tratamiento de inmunoterapia.
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
ZA202205813B (en) Trpv1 epitopes and antibodies
WO2021067633A3 (en) Kir3dl3 is an inhibitory receptor of the immune system and uses thereof
WO2020186111A3 (en) Vista-binding antibodies and uses thereof
MX2021004603A (es) Dosificacion.